ABBV vs XOM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-19.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Exxon Mobil Corporation · Energy
$163.18
+10.3% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
XOM has more upside to fair value
(+10.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
XOM |
| Current Price |
$261.70 |
$163.18 |
| Fair Value Estimate |
$259.04 |
$179.98 |
| Upside to Fair Value |
-1.0%
|
+10.3%
|
| Market Cap |
$462.4B |
$676.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
9.9x
|
| Price / Sales |
7.2x
|
1.9x
|
| Price / FCF |
23.6x
|
22.3x
|
| Revenue Growth YoY |
+10.2%
|
+44.1%
|
| Gross Margin |
71.5%
|
25.1%
|
| Operating Margin |
29.3%
|
10.7%
|
| Return on Equity |
-136.5%
|
12.7%
|
| Dividend Yield |
2.61% |
2.52% |
| FCF Yield |
4.25%
|
4.49%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Exxon Mobil is the largest integrated oil and gas major in the United States, operating across Upstream exploration and production, Downstream refining and fuels marketing, and Chemical manufacturing, with roughly 57,900 employees and a portfolio that spans conventional crude and natural gas, LNG, petrochemicals, and early-stage carbon capture, hydrogen, and biofuels ventures. The business qualit…
Accumulation Zones
| Metric |
ABBV |
XOM |
| Zone Low |
$194.28 |
$134.98 |
| Zone High |
$220.18 |
$152.98 |
| In Buy Zone? |
No
|
No
|